Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue

被引:31
作者
Darb-Esfahani, Silvia [1 ]
Wirtz, Ralph M. [2 ]
Sinn, Bruno V. [1 ]
Budczies, Jan [1 ]
Noske, Aurelia [1 ]
Weichert, Wilko [1 ]
Faggad, Areeg [1 ]
Scharff, Susanne [2 ]
Sehouli, Jalid [3 ]
Oskay-Oezcelik, Guelten [3 ]
Zamagni, Claudio [4 ]
De Iaco, Pierandrea [5 ]
Martoni, Andrea [4 ]
Dietel, Manfred [1 ]
Denkert, Carsten [1 ]
机构
[1] Charite, Inst Pathol, D-10117 Berlin, Germany
[2] Siemens Healthcare Diagnost, Cologne, Germany
[3] Charite, Dept Obstet & Gynaecol, D-10117 Berlin, Germany
[4] St Orsola Marcello Malpighi Hosp, Med Oncol Unit, Bologna, Italy
[5] Univ Bologna, Obstet & Gynaecol Unit, Bologna, Italy
关键词
GENE-EXPRESSION CHANGES; EARLY BREAST-CANCER; PHASE-II TRIAL; PROGESTERONE-RECEPTOR; REPLACEMENT THERAPY; STEROID-RECEPTORS; GROWTH-FACTOR; TAMOXIFEN; ALPHA; ASSAY;
D O I
10.1677/ERC-08-0338
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidemiological and cell culture studies indicate that ovarian carcinoma growth is dependent on estrogen stimulation. However, possibly due to the lack of a reliable biomarker that helps to select patients according to prognostically relevant estrogen receptor (ER) levels, clinical trials using anti-estrogenic therapeutics in ovarian carcinoma have had inconsistent results Therefore, we tested if ER expression analysis by a quantitative method might be useful in this regard in formalin-fixed paraffin-embedded (FFPE) tissue In a study group of 114 primary ovarian carcinomas expression of estrogen receptor 1 (ESR1) mRNA was analyzed using a new method for RNA extraction from FFPE tissue that is based on magnetic beads, followed by kinetic PCR. The prognostic impact of ESR1 mRNA expression was investigated and compared to ER alpha protein expression as determined by immunohistochemistry In univariate survival analysis the expression level of ESR1 mRNA was a significant positive prognostic factor for patient survival (hazard ratio (HR) 0.230 (confidence interval (CI) 0.102-0516), P=0.002) ER alpha protein expression was correlated to ESR1 mRNA expression (P=0.0001), however, ER alpha protein expression did not provide statistically significant prognostic information. In multivariate analysis, ESR1 mRNA expression emerged as a prognostic factor, independent of stage, grade, residual tumor mass, age, and ER alpha protein expression (HR 0.227 (CI 0.078-0.656), P=0.006) Our results indicate that the determination of ESR1 levels by kinetic PCR may be superior to immunohistochemical methods in assessment of biologically relevant levels of ER expression in ovarian carcinoma, and is feasible in routinely used FFPE tissue. Endocrine-Related Cancer (2009) 16 1229-1239
引用
收藏
页码:1229 / 1239
页数:11
相关论文
共 51 条
[1]   HORMONAL PALLIATION OF CHEMORESISTANT OVARIAN-CANCER - 3 CONSECUTIVE PHASE-II TRIALS OF THE MID-ATLANTIC ONCOLOGY PROGRAM [J].
AHLGREN, JD ;
ELLISON, NM ;
GOTTLIEB, RJ ;
LALUNA, F ;
LOKICH, JJ ;
SINCLAIR, PR ;
UENO, W ;
WAMPLER, GL ;
YEUNG, KY ;
ALT, D ;
FRYER, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :1957-1968
[2]   Loss of ERβ expression as a common step in estrogen-dependent tumor progression [J].
Bardin, A ;
Boulle, N ;
Lazennec, G ;
Vignon, F ;
Pujol, P .
ENDOCRINE-RELATED CANCER, 2004, 11 (03) :537-551
[3]  
Bookman MA, 2006, J CLIN ONCOL, V24, p256S
[4]  
Bowman A, 2002, CLIN CANCER RES, V8, P2233
[5]   Estrogen receptor subtypes in ovarian cancer - A clinical correlation [J].
Chan, Karen K. L. ;
Wei, Na ;
Liu, Stephanie S. ;
Xiao-Yun, Liao ;
Cheung, Annie N. ;
Ngan, Hextan Y. S. .
OBSTETRICS AND GYNECOLOGY, 2008, 111 (01) :144-151
[6]   Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients [J].
Chang, Jenny C. ;
Makris, Andreas ;
Gutierrez, M. Carolina ;
Hilsenbeck, Susan G. ;
Hackett, James R. ;
Jeong, Jennie ;
Liu, Mei-Lan ;
Baker, Joffre ;
Clark-Langone, Kim ;
Baehner, Frederick L. ;
Sexton, Krsytal ;
Mohsin, Syed ;
Gray, Tara ;
Alvarez, Laura ;
Chamness, Gary C. ;
Osborne, C. Kent ;
Shak, Steven .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (02) :233-240
[7]   A prospective study of postmenopausal hormone use and ovarian cancer risk [J].
Danforth, K. N. ;
Tworoger, S. S. ;
Hecht, J. L. ;
Rosner, B. A. ;
Colditz, G. A. ;
Hankinson, S. E. .
BRITISH JOURNAL OF CANCER, 2007, 96 (01) :151-156
[8]   Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: Enhancement of DNA platination as a possible mechanism [J].
Ercoli, A ;
Scambia, G ;
DeVincenzo, R ;
Alimonti, A ;
Petrucci, F ;
Fattorossi, A ;
Isola, G ;
Panici, PB ;
Caroli, S ;
Mancuso, S .
CANCER LETTERS, 1996, 108 (01) :7-14
[9]   Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin [J].
Fiala, Milan ;
Liu, Philip T. ;
Espinosa-Jeffrey, Araceli ;
Rosenthal, Mark J. ;
Bernard, George ;
Ringman, John M. ;
Sayre, James ;
Zhang, Laura ;
Zaghi, Justin ;
Dejbakhsh, Sheila ;
Chiang, Ben ;
Hui, James ;
Mahanian, Michelle ;
Baghaee, Anita ;
Hong, Pamela ;
Cashman, John .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) :12849-12854
[10]   INFLUENCE OF TUMOR ESTROGEN AND PROGESTERONE-RECEPTOR LEVELS ON THE RESPONSE TO TAMOXIFEN AND CHEMOTHERAPY IN PRIMARY BREAST-CANCER [J].
FISHER, B ;
REDMOND, C ;
BROWN, A ;
WICKERHAM, DL ;
WOLMARK, N ;
ALLEGRA, J ;
ESCHER, G ;
LIPPMAN, M ;
SAVLOV, E ;
WITTLIFF, J ;
FISHER, ER ;
PLOTKIN, D ;
BOWMAN, D ;
WOLTER, J ;
BORNSTEIN, R ;
DESSER, R ;
FRELICK, R .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (04) :227-241